Few ailments have frustrated medical science and the pharmaceutical industry for years on end in the way Alzheimer's has, as many have tried – and failed – to develop just one efficient treatment for the disease.

For this reason, the so-called Elad trial, which tests Novo Nordisk's liraglutide, which by the name of Victoza is already a well-established treatment for type II diabetes, as a treatment for Alzheimer's disease.